In a pooled analysis of the two monotherapy studies, the add-on to metformin study, and the add-on to pioglitazone study, the incidence of selected gastrointestinal adverse reactions in patients treated with JANUVIA was as follows: abdominal pain (JANUVIA 100 mg, 2.3%
Most people who persist through the initial adjustment periods achieve substantial weight loss that makes the temporary discomfort worthwhile
Rising clinical demand for pharmacological therapies targeting post-bariatric surgery weight regain is a key anti-obesity drugs market driver
Proteomic changes upon treatment with semaglutide in individuals with obesity
We evaluate each person individually to determine if semaglutide is appropriate and safe for them
The Mayo Clinic shares that those most at risk of low levels include (5): people who dont consume enough vitamin B12 in their diet people diagnosed with pernicious anemia people whove had gastric surgeries people with intestinal issues, such as celiac or Crohns disease People following a vegetarian diet are especially at risk of deficiency